Equity Overview
Price & Market Data
Price: $4.17
Daily Change: +$0.02 / 0.48%
Daily Range: $4.00 - $4.18
Market Cap: $28,176,982
Daily Volume: 11,754
Performance Metrics
1 Week: 6.65%
1 Month: 19.48%
3 Months: 12.70%
6 Months: -6.29%
1 Year: -1.18%
YTD: -15.42%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.